drugset / Trial / NCT02759029
Development of Treatment Algorithm for Eradication of Helicobacter Pylori Based on Antibiotic Susceptibility Test
RandomizedParallel-groupOpen-labelTreatment
Summary
Helicobacter pylori eradication (H. pylori) rates with clarithromycin-based triple therapy are declining, and an alternative strategy is needed urgently. The investigators sought to compare the efficacy of pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy vs. concomitant therapy for H. pylori eradication in a region with high rates of multiple drug resistance.
Timeline
- Start
- 2016-03
- Primary completion
- 2018-02
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amoxacillin | Unknown | 1 g | Oral |
| Comparator | Bismuth Potassium Citrate | Unknown | 300 mg | Oral |
| Comparator | Clarithromycin | Small molecule | 500 mg | Oral |
| Comparator | Levofloxacin | Small molecule | 500 mg | Oral |
| Comparator | Metronidazole | Small molecule | 500 mg | Oral |
| Comparator | Pantoprazole | Other / unclassified | 40 mg | Oral |
| Comparator | Tetracycline | Unknown | 500 mg | Oral |